219 related articles for article (PubMed ID: 22405602)
1. Antipsychotics in pediatric and adolescent patients: a review of comparative safety data.
Ben Amor L
J Affect Disord; 2012; 138 Suppl():S22-30. PubMed ID: 22405602
[TBL] [Abstract][Full Text] [Related]
2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
3. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
Toren P; Ratner S; Laor N; Weizman A
Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.
Edwards SJ; Smith CJ
Clin Ther; 2009 Jun; 31 Pt 1():1345-59. PubMed ID: 19698898
[TBL] [Abstract][Full Text] [Related]
5. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia.
Correll CU
J Clin Psychiatry; 2011 Aug; 72(8):e26. PubMed ID: 21899814
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
[TBL] [Abstract][Full Text] [Related]
8. Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review.
Druyts E; Zoratti MJ; Toor K; Wu P; Kanji S; Rabheru K; Mills EJ; Thorlund K
BMC Pediatr; 2016 Nov; 16(1):181. PubMed ID: 27825323
[TBL] [Abstract][Full Text] [Related]
9. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
10. The safety and tolerability of atypical antipsychotics in bipolar disorder.
Seemüller F; Forsthoff A; Dittmann S; Born C; Bernhard B; Severus WE; Grunze H
Expert Opin Drug Saf; 2005 Sep; 4(5):849-68. PubMed ID: 16111448
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
12. A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics.
Lee ES; Vidal C; Findling RL
J Child Adolesc Psychopharmacol; 2018 Nov; 28(9):582-605. PubMed ID: 30312108
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.
Cohen D; Bonnot O; Bodeau N; Consoli A; Laurent C
J Clin Psychopharmacol; 2012 Jun; 32(3):309-16. PubMed ID: 22544019
[TBL] [Abstract][Full Text] [Related]
14. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
Maayan L; Correll CU
J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
[TBL] [Abstract][Full Text] [Related]
15. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.
Zuddas A; Zanni R; Usala T
Eur Neuropsychopharmacol; 2011 Aug; 21(8):600-20. PubMed ID: 21550212
[TBL] [Abstract][Full Text] [Related]
16. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
Citrome L; Kalsekar I; Guo Z; Laubmeier K; Hebden T
Clin Ther; 2013 Dec; 35(12):1867-75. PubMed ID: 24119767
[TBL] [Abstract][Full Text] [Related]
17. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.
McConville BJ; Sorter MT
J Clin Psychiatry; 2004; 65 Suppl 6():20-9. PubMed ID: 15104523
[TBL] [Abstract][Full Text] [Related]
18. Safety of olanzapine use in adolescents.
Schulz C; Haight RJ
Expert Opin Drug Saf; 2013 Sep; 12(5):777-82. PubMed ID: 23876012
[TBL] [Abstract][Full Text] [Related]
19. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials.
Jensen PS; Buitelaar J; Pandina GJ; Binder C; Haas M
Eur Child Adolesc Psychiatry; 2007 Mar; 16(2):104-20. PubMed ID: 17075688
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
